Evidence map›Paper›PMID 23758675›Full record

ArticleBMC medical genomics2013

Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing.

Poornima Bhat-Nakshatri, Eun-Kyung Song, Nikail R Collins, Vladimir N Uversky, A Keith Dunker, Bert W O'Malley, Tim R Geistlinger, Jason S Carroll, Myles Brown, Harikrishna Nakshatri

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Connecting the dots: chromatin and alternative splicing in EMT.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2016
    Review
  14. Article
  15. CRH-R splicing in estrogen-sensitive breast cancer.Cell cycle (Georgetown, Tex.) · 2014
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Poornima Bhat-NakshatriDepartment of Surgery, Indiana University School of Medicine, 980 West Walnut Street, Indianapolis, IN 46202, USA.
Eun-Kyung Song
Nikail R Collins
Vladimir N Uversky
A Keith Dunker
Bert W O'Malley
Tim R Geistlinger
Jason S Carroll
Myles Brown
Harikrishna Nakshatri
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · USAmyris (United States) · USBaylor College of Medicine · USDana-Farber Cancer Institute · USFlorida College · USUniversity of Cambridge · GB

Funding

SEX HORMONE RECEPTOR COMPONENTS AND THE CELL GENOMER01HD007857 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$14.6M
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLSR01CA089153 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI NAKSHATRI, HARIKRISHNA · 2001 to 2005
$1.2M
NCI NIH HHS CA89153NICHD NIH HHS R01 HD007857
6 · The paper itself

Abstract

backgroundAlternative splicing is critical for generating complex proteomes in response to extracellular signals. Nuclear receptors including estrogen receptor alpha (ERα) and their ligands promote alternative splicing. The endogenous targets of ERα:estradiol (E2)-mediated alternative splicing and the influence of extracellular kinases that phosphorylate ERα on E2-induced splicing are unknown.

methodsMCF-7 and its anti-estrogen derivatives were used for the majority of the assays. CD44 mini gene was used to measure the effect of E2 and AKT on alternative splicing. ExonHit array analysis was performed to identify E2 and AKT-regulated endogenous alternatively spliced apoptosis-related genes. Quantitative reverse transcription polymerase chain reaction was performed to verify alternative splicing. ERα binding to alternatively spliced genes was verified by chromatin immunoprecipitation assay. Bromodeoxyuridine incorporation-ELISA and Annexin V labeling assays were done to measure cell proliferation and apoptosis, respectively.

resultsWe identified the targets of E2-induced alternative splicing and deconstructed some of the mechanisms surrounding E2-induced splicing by combining splice array with ERα cistrome and gene expression array. E2-induced alternatively spliced genes fall into at least two subgroups: coupled to E2-regulated transcription and ERα binding to the gene without an effect on rate of transcription. Further, AKT, which phosphorylates both ERα and splicing factors, influenced ERα:E2 dependent splicing in a gene-specific manner. Genes that are alternatively spliced include FAS/CD95, FGFR2, and AXIN-1. E2 increased the expression of FGFR2 C1 isoform but reduced C3 isoform at mRNA level. E2-induced alternative splicing of FAS and FGFR2 in MCF-7 cells correlated with resistance to FAS activation-induced apoptosis and response to keratinocyte growth factor (KGF), respectively. Resistance of MCF-7 breast cancer cells to the anti-estrogen tamoxifen was associated with ERα-dependent overexpression of FGFR2, whereas resistance to fulvestrant was associated with ERα-dependent isoform switching, which correlated with altered response to KGF.

conclusionE2 may partly alter cellular proteome through alternative splicing uncoupled to its effects on transcription initiation and aberration in E2-induced alternative splicing events may influence response to anti-estrogens.

Indexed as

Alternative SplicingBinding SitesEstradiolEstrogen Receptor alphafas ReceptorHumansHyaluronan ReceptorsMCF-7 CellsMutationPhosphorylationProtein BindingProtein IsoformsProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 2RNA InterferenceRNA, MessengerEstradiolEstrogen Receptor alphafas ReceptorHyaluronan ReceptorsProtein IsoformsProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 2RNA, MessengerRNA, Small Interfering

Identifiers

PMID23758675
PMCPMC3687557
OpenAlexW2074132123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.